




# Bring K Pro to your data

K Pro comes to your data, no transfer needed.

K Pro connects to your data on your preferred platform with no need to transfer your data.

You retain all permissions over data access giving you the power of K Pro's analytic and data layer, without having to modify your system structure.



**DATA**

## AI ready data

Your data is curated so that K Pro's agentic system can compare data between modalities and datasets, as well as enrich data through Owkin's proprietary AI models.

### Enhanced interoperability

K Pro is built for interoperability between datasets. K Pro ensures minimal data contracts and embeds data into a semantic ontology layer.

### AI-ready data preparation

User data is prepared for K Pro through a combination of agentic workflows and modality specific pipelines.

### Data enrichment

Owkin's proprietary AI is available to enrich your data with key signals (e.g. cell-type detection, bulk-deconvolution signatures).

### Indication optimization

K Pro is optimized for oncology and I&I use cases. Other kinds of disease areas and data modalities can be onboarded on request.




### K Pro's broad multiomic data capability

- Clinical data
- Bulk RNA-seq
- Single-cell RNAseq
- Whole Exome Sequencing
- Spatial Transcriptomics
- H&E imaging / histology
- Proteomics

# K Pro unlocks your data & complements it with Owkin multimodal data

Ask questions in natural language to solve your pipeline challenges from early portfolio decisions to clinical trial decisions.



Complement your data with Owkin's proprietary data catalogue

- **104 hospitals**  
World-largest patient data network.
- **2700 cancer samples, 11 tumor types**  
MOSAIC spatial & multiomics dataset.

**K PRO**

## The AI Scientist built for every step of the pipeline

State-of-the-art AI analysis to better understand your data.



### Prioritize targets

Rank therapeutic targets and gene candidates using statistical evidence from TCGA and MOSAIC datasets.



### Assess tractability & druggability

Evaluate target tractability, safety profiles, and therapeutic potential using curated databases.



### Characterize patient subgroups

Identify distinct populations based on multi-omics profiles and clinical outcomes.




### Validate biomarkers across modalities

Test biomarkers and hypotheses across bulk RNA-seq, single-cell, spatial, and clinical data.



### Generate comprehensive reports

Create publication-ready statistical reports for gene/target assessment, biomarker prioritization, and patent landscape analysis.



### Connect biology to clinical outcomes

Integrate genomic, transcriptomic, and immune data to identify therapeutic opportunities and predict treatment response.



## Book a demo

Discover how K Pro can transform your drug discovery and development. Scan the QR code to book a demo with our team to explore how we can support your specific needs.



Get in touch with us at [owkin.com/contact](https://owkin.com/contact)

© 2026 Owkin, Inc | Public information | Ref. 066V1

 **OWKIN.COM**